Abstract
Master protocol studies typically use an overarching protocol to answer several questions by guiding a variety of sub-studies. These sub-studies can incorporate multiple diseases, therapies, or both. Although this innovative approach offers many benefits, including the ability to deliver clinical research that is more patient-centric and efficient, several common barriers curtail widespread adoption. The Clinical Trials Transformation Initiative (CTTI) convened industry representatives, regulatory agencies, patient groups, and academic institutions to identify emerging best practices and develop resources designed to help sponsors and other stakeholders overcome these challenges. We first identify some broad changes needed in the clinical trials ecosystem to facilitate mainstream adoption of master protocol studies, and we subsequently summarize CTTI’s resources designed to support this effort.
Full Text
Topics from this Paper
Clinical Trials Transformation Initiative
Master Protocols
Master Protocol
Broad Changes
Regulatory Agencies
+ Show 5 more
Create a personalized feed of these topics
Get StartedSimilar Papers
Journal of Hepatology
Feb 1, 2023
Clinical trials (London, England)
Sep 9, 2022
Clinical and Translational Science
Aug 1, 2014
Clinical Cancer Research
Jan 15, 2014
Clinical Therapeutics
Jul 1, 2020
Therapeutic innovation & regulatory science
Aug 24, 2023
Therapeutic innovation & regulatory science
Aug 24, 2023
Contemporary Clinical Trials Communications
Sep 1, 2019
Clinical Trials
Feb 1, 2018
Clinical Trials
Apr 20, 2016
Clinical Journal of the American Society of Nephrology
Oct 1, 2022
Developmental Medicine & Child Neurology
Apr 2, 2023
Advances in Pulmonary Hypertension
Aug 1, 2020
Contemporary Clinical Trials
Feb 1, 2020
Clinical Trials
Clinical Trials
Jul 29, 2023
Clinical Trials
Jul 26, 2023
Clinical Trials
Jul 13, 2023
Clinical Trials
Jun 20, 2023
Clinical Trials
Jun 2, 2023
Clinical Trials
Jun 2, 2023
Clinical Trials
May 18, 2023
Clinical Trials
Feb 28, 2023
Clinical Trials
Feb 6, 2023
Clinical Trials
Feb 3, 2023